Cel Sci (CVM) EPS (Basic) Growth (3y) (2013 - 2026)
Cel Sci (CVM) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | -38.31% |
| 10 | Cel Sci | 2.15 Mn | -4.39 Mn | - | 12.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68% |
| Dec 31, 2025 | 4.00% |
| Sep 30, 2025 | -8.76% |
| Jun 30, 2025 | -11.77% |
| Mar 31, 2025 | -17.09% |
| Dec 31, 2024 | -22.27% |
| Sep 30, 2024 | -20.09% |
| Jun 30, 2024 | 14.56% |
| Mar 31, 2024 | 20.92% |
| Dec 31, 2023 | 12.62% |
| Sep 30, 2023 | -5.44% |
| Jun 30, 2023 | 11.67% |
| Mar 31, 2023 | 8.68% |
| Dec 31, 2022 | -5.43% |
| Sep 30, 2022 | -10.67% |
| Jun 30, 2022 | 14.33% |
| Mar 31, 2022 | -0.95% |
| Dec 31, 2021 | -87.38% |
| Sep 30, 2021 | 38.78% |
| Jun 30, 2021 | 14.82% |